NMN vs NR: The NAD+ Precursor Debate
Nicotinamide adenine dinucleotide (NAD+) levels decline predictably with age, correlating strongly with mitochondrial dysfunction. The debate over which precursor—NMN or NR—is superior for restoring systemic NAD+ remains one of the most contentious topics in longevity medicine.
The Pharmacokinetic Problem
The central issue is cellular uptake. NAD+ itself is too large to cross the cell membrane efficiently. Precursors must be used. Nicotinamide Riboside (NR) is a smaller molecule that enters cells via equilibrative nucleoside transporters (ENTs) and is then phosphorylated into NMN by the NRK1/2 enzymes, before finally being converted to NAD+.
Nicotinamide Mononucleotide (NMN) is larger. Historically, it was believed that NMN had to be dephosphorylated externally into NR to enter the cell. However, the discovery of the Slc12a8 transporter—which appears to transport NMN directly into the cell in the gut—complicated this narrative.
Clinical Trial Data (Human)
While mouse models heavily favor NMN (often due to the specific work of the Sinclair lab at Harvard), human data paints a more nuanced picture.
| Compound | Typical Dose | NAD+ Increase (Blood) | Noted Clinical Endpoints |
|---|---|---|---|
| NR (Niagen) | 300mg - 1000mg | ~40-90% | Mild reduction in inflammatory markers; minor improvements in physical performance in older cohorts. |
| NMN | 250mg - 1000mg | ~38-100% | Improved insulin sensitivity in prediabetic postmenopausal women (250mg/day); improved aerobic capacity in amateur runners (1200mg/day). |
The Methylation Sink
Both precursors process into Nicotinamide (NAM), which must be methylated to be excreted (as MeNAM). High doses of either precursor without adequate methyl donors (like TMG or betaine) may theoretically deplete the body's methyl pool, impacting homocysteine levels. Clinical evidence for this at standard doses (under 1000mg) is sparse, but co-supplementation with TMG is standard clinical practice.
Verdict & Dosing Protocols
Currently, NMN shows slightly more robust functional clinical endpoints in human trials, particularly regarding metabolic flexibility and aerobic capacity. NR possesses more comprehensive safety data due to its longer time on the market and GRAS status.
- Standard Protocol: 500mg NMN or 300mg NR daily, taken in the morning (to align with the circadian rhythm of SIRT1 activity).
- Adjuncts: 500mg Trimethylglycine (TMG) to support methylation.
- Delivery: Liposomal NMN is gaining traction due to the rapid degradation of un-encapsulated NMN in gastric acid, though robust human pharmacokinetic data comparing liposomal vs standard powder is still pending.
FDA Regulatory Notice (NMN)
In late 2022, the FDA stated that NMN could no longer be sold as a dietary supplement because it was under investigation as a new drug (by Metro International Biotech). The situation is ongoing, and availability fluctuates.